GabapentinMyoclonus in patients with end-stage renal disease: 3 case reports

被引：0
作者：
机构：
来源：
Reactions Weekly | 2005年 / 1052卷 / 1期
关键词：
Public Health; Renal Disease; Gabapentin; Normal Activity; Dosage Increase;
D O I：
10.2165/00128415-200510520-00033
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：10 / 10
相关论文
共 50 条
  • [41] Reducing hospital readmissions in patients with end-stage kidney disease
    Mathew, Anna T.
    Strippoli, Giovanni F. M.
    Ruospo, Marinella
    Fishbane, Steven
    KIDNEY INTERNATIONAL, 2015, 88 (06) : 1250 - 1260
  • [42] The importance of psychiatric disorders in end-stage kidney disease patients
    Lee, Eun
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2022, 41 (02) : 133 - 135
  • [43] Geriatric Assessment in Elderly Patients with End-Stage Kidney Disease
    Goto, Namiko A.
    van Loon, Ismay N.
    Morpey, Moira I.
    Verhaar, Marianne C.
    Willems, Hanna C.
    Emmelot-Vonk, Marielle H.
    Bots, Michiel L.
    Boereboom, Franciscus T. J.
    Hamaker, Marije E.
    NEPHRON, 2019, 141 (01) : 41 - 48
  • [44] Multilayer network analysis in patients with end-stage kidney disease
    Yi, Jiyae
    Heo, Chang Min
    Park, Bong Soo
    Lee, Yoo Jin
    Park, Sihyung
    Kim, Yang Wook
    Lee, Dong Ah
    Park, Kang Min
    Kim, Jinseung
    Ko, Junghae
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [45] Incidence of arrhythmias during dialysis in intensive-care-unit patients with end-stage renal disease
    Chelu, Mihail Gabriel
    Ibrahim, Yahya
    Shannoon, Farah
    Singh, Navneet
    Saeed, Mohammad
    Razavi, Mehdi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 174 (03) : 753 - 754
  • [46] Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
    Teddy Kosoglou
    Walter K. Kraft
    Bharath Kumar
    Paul Statkevich
    Fengjuan Xuan
    Lei Ma
    Lisa K. Jennings
    James E. Schiller
    Ronald B. Langdon
    David L. Cutler
    European Journal of Clinical Pharmacology, 2012, 68 : 1049 - 1056
  • [47] Psychometric Properties of the Death Anxiety Scale-Extended among Patients with End-Stage Renal Disease
    Nia, Hamid Sharif
    Sharif, Saeed Pahlevan
    Koocher, Gerald P.
    Yaghoobzadeh, Ameneh
    Haghdoost, Ali Akbar
    Win, Ma Thin Mar
    Soleimani, Mohammad Ali
    OMEGA-JOURNAL OF DEATH AND DYING, 2020, 80 (03) : 380 - 396
  • [48] Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
    Kosoglou, Teddy
    Kraft, Walter K.
    Kumar, Bharath
    Statkevich, Paul
    Xuan, Fengjuan
    Ma, Lei
    Jennings, Lisa K.
    Schiller, James E.
    Langdon, Ronald B.
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (07) : 1049 - 1056
  • [49] End-stage kidney disease in Fiji
    Krishnan, Amrish
    Chandra, Yogeshni
    Malani, Joji
    Jesudason, Shilpanjali
    Sen, Shaundeep
    Ritchie, Angus G.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (04) : 461 - 466
  • [50] Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease
    Blacher, J
    Guerin, AP
    Pannier, B
    Marchais, SJ
    London, GM
    HYPERTENSION, 2001, 38 (04) : 938 - 942
12345